Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 15/20 | 0.55 |
| ▸ | MAOA | P21397 | 6/20 | 0.48 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547158 | 0.89 | NISCH (0.46) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7553914 | 0.89 | NISCH (0.46) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7547001 | 0.85 | NISCH (0.49) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7548321 | 0.84 | NISCH (0.66) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7554277 | 0.84 | NISCH (0.50) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7548769 | 0.83 | NISCH (0.51) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7546294 | 0.81 | NISCH (0.52) | NISCHMAOAMAOBADRA1AADRA1D | |
| SCHEMBL7550085 | 0.81 | NISCH (0.51) | NISCHMAOAMAOBADRA1AADRA1D | |
| Midaglizole SCHEMBL114554 | 0.80 | NISCH (0.74) | NISCHMAOAMAOBADRA1AADRA1D | |
| Midaglizole SCHEMBL30029057 | 0.80 | NISCH (0.74) | NISCHMAOAMAOBADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | claimed |
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | disclosed |
| WO-2002038559-A1 | 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS | NOVO NORDISK A/S (DK) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | SLC5A2, GPR119, SLC5A1 | NISCH 448/4885MAOA 3214/4885MAOB 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.